Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy

NCT05126758 is registered in ClinicalTrials.gov with Capricor Inc. as lead sponsor.

NCT NCT05126758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05126758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
Lead sponsor
Capricor Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 22, 2022
Completion date
March 31, 2027
Enrollment
106 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

genetic diseases, inborn, genetic diseases, x-linked, muscular diseases, muscular disorders, atrophic, muscular dystrophies, muscular dystrophy, duchenne, nervous system diseases, neuromuscular diseases